Project Grant R43HL174179
Award Date
5/1/24
Completion Date
7/31/25
Dollars Obligated
$539K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Dayton, OH 45419, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), awarded a $294,993 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Sensoriis Inc. in Edmonds, WA. The goal of this 1-year project is to develop a Zebrafish Automatic Cardiovascular Assessment System (ZACAS) to provide a fast, economic, and easy solution for researchers to assess cardiac functions in developing zebrafish embryos. Specifically, the project...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $400,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Electronic Biosciences, Inc., a small biotechnology company in San Diego, California. The grant supports the development of a new analytical testing device for the quantitative characterization of lipoprotein particles in blood. Lipoproteins are an important indicator of cardiovascular disease risk, as certain lipoprotein classes contribute to...
The National Heart Lung and Blood Institute (NHLBI), through its Cardiovascular Diseases Research grant program (CFDA 93.837), awarded a $499,881 project grant to Dynocardia, Inc. to complete the design verification and validation of their Vitrack, a continuous non-invasive blood pressure (CNIBP) monitoring device. The Vitrack is a cuff-less, wrist-wearable device that utilizes proprietary optomechanical sensor and computer vision technology to provide accurate, continuous blood pressure...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant of $1,283,558 to the Massachusetts Institute of Technology (MIT) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The purpose of this 4-year grant, with a start date of August 1, 2024, is to develop and demonstrate the concept of Multi-Electroplasmonic Nanoantenna Arrays (MENAS) - a breakthrough wireless technology for high-resolution, intracellular electrophysiological recording of...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, awarded a $310,948 Project Grant to Minnesota Healthsolutions Corporation, a for-profit woman-owned small business, on September 15, 2023. The grant funds the development of an adaptable platform to support patients with behavior change interventions aimed at improving adherence to treatment and prevention for multiple chronic diseases. The platform will utilize remote...
This $498,638 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of a novel mobile health system for remote monitoring of patients with chronic obstructive pulmonary disease (COPD). The project, titled "Bilateral Acoustic Sensing and Automated Breathing Segmentation for Remote Monitoring of Patients with COPD: A Longitudinal Study," aims to enhance adherence to remote...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $863,328 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Aquillius Corp, a San Diego-based woman-owned small business. The grant supports the development of a wearable graphene respiratory sensor for early detection and continuous monitoring of asthma, particularly in children. The key objectives are to: (I) optimize the sensor's performance...
The $265,347 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports Functional Fluidics Inc.'s development of a rapid, integrated test for assessing red blood cell sickling in sickle cell disease. The key product is a stand-alone, potentially CLIA-waived point-of-care device with disposable cartridges to monitor patient condition and treatment efficacy, especially for drugs affecting...
The National Heart, Lung, and Blood Institute (NHLBI) awarded Duke University a $238,943 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to develop an automated platform for accurately tracking urine output among hospitalized heart failure patients. The goal is to mitigate the measurement inaccuracies and treatment delays caused by the current manual urine monitoring process, which exposes hospital staff to hazardous chemicals and pathogens. The project aims to...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), awarded a $735,939 Project Grant to The General Hospital Corporation (doing business as Massachusetts General Hospital) on August 26, 2024. The grant aims to develop and validate new technology for accurate, rapid, point-of-care, and high-frequency blood gas analysis. Specifically, the project will create a miniaturized and automated device that attaches...